Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2018

Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2018


  • Products Id :- GDME0663EPD
  • |
  • Pages: 148
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Liver Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Liver Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2018" provides an overview of Liver Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Liver Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Liver Cancer Diagnostic Tests under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Liver Cancer Diagnostic Tests and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry.

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Liver Cancer Diagnostic Tests under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Liver Cancer Diagnostic Tests Overview 8

3 Products under Development 9

3.1 Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 9

3.2 Liver Cancer Diagnostic Tests-Pipeline Products by Territory 10

3.3 Liver Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 11

3.4 Liver Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 12

4 Liver Cancer Diagnostic Tests-Pipeline Products under Development by Companies 13

4.1 Liver Cancer Companies-Pipeline Products by Stage of Development 13

4.2 Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 15

5 Liver Cancer Diagnostic Tests Companies and Product Overview 17

5.1 Abbott Diagnostics Company Overview 17

5.2 Abcodia Ltd Company Overview 22

5.3 AXO Science SAS Company Overview 23

5.4 BioMark Technologies Inc Company Overview 26

5.5 Bioprognos SL Company Overview 27

5.6 China Sky One Medical Inc Company Overview 28

5.7 Digna Biotech SL Company Overview 29

5.8 Exact Sciences Corp Company Overview 31

5.9 Fujirebio Diagnostics Inc Company Overview 33

5.10 German Cancer Research Center Company Overview 34

5.11 Glycotest Inc Company Overview 35

5.12 ImCare Biotech LLC Company Overview 36

5.13 Imperial College London Company Overview 37

5.14 IntegraGen SA Company Overview 38

5.15 Matrix-Bio, Inc. Company Overview 39

5.16 Medical University of South Carolina Company Overview 41

5.17 Medical University of Vienna Company Overview 42

5.18 NanoString Technologies Inc Company Overview 43

5.19 Oncimmune (USA) LLC Company Overview 44

5.20 Orion Genomics LLC Company Overview 45

5.21 PleX Diagnostics Inc (Inactive) Company Overview 46

5.22 ProMIS Neurosciences Inc Company Overview 47

5.23 Proplex Technologies Llc Company Overview 48

5.24 Proteome Sciences Plc Company Overview 49

5.25 Roche Diagnostics International Ltd Company Overview 50

5.26 University of Louisville Company Overview 52

5.27 University of Rochester Company Overview 53

5.28 Ventana Medical Systems Inc Company Overview 54

5.29 Viomics Inc. Company Overview 55

5.30 XEPTAGEN SpA Company Overview 56

5.31 Ymir Genomics LLC. Company Overview 60

6 Liver Cancer Diagnostic Tests-Recent Developments 61

6.1 Jun 22, 2018: Trovagene Announces Senior Management Change 61

6.2 Jun 06, 2018: Pfizer Opens Call for Proposals for Neuroscience Start-ups to Apply for LabCentral Residency 61

6.3 Jun 05, 2018: Exact Sciences, Mayo Clinic Researchers Identify Blood-Based DNA Biomarker Panel to Accurately Diagnose Hepatocellular Carcinoma 62

6.4 Jun 05, 2018: Mayo Clinic researchers take a step closer to developing a DNA test for liver cancer 63

6.5 May 14, 2018: Oncimmune Launches EarlyCDT-Liver Test in the US 63

7 Appendix 145

7.1 Methodology 145

7.2 About GlobalData 148

7.3 Contact Us 148

7.4 Disclaimer 148

1.2 List of Figures

Figure 1: Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 9

Figure 2: Liver Cancer Diagnostic Tests-Pipeline Products by Territory 10

Figure 3: Liver Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 11

Figure 4: Liver Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 12

1.1 List of Tables

Table 1: Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 9

Table 2: Liver Cancer Diagnostic Tests-Pipeline Products by Territory 10

Table 3: Liver Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 11

Table 4: Liver Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 12

Table 5: Liver Cancer Companies-Pipeline Products by Stage of Development 13

Table 6: Liver Cancer Diagnostic Tests-Pipeline Products by Stage of Development 15

Table 7: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 17

Table 8: ARCHITECT c16000 System-PIVKA Assay-Product Status 17

Table 9: ARCHITECT c16000 System-PIVKA Assay-Product Description 18

Table 10: ARCHITECT c4000 System-PIVKA Assay-Product Status 18

Table 11: ARCHITECT c4000 System-PIVKA Assay-Product Description 18

Table 12: ARCHITECT c8000 System-PIVKA Assay-Product Status 19

Table 13: ARCHITECT c8000 System-PIVKA Assay-Product Description 19

Table 14: ARCHITECT ci16200 Integrated System-PIVKA Assay-Product Status 19

Table 15: ARCHITECT ci16200 Integrated System-PIVKA Assay-Product Description 19

Table 16: ARCHITECT ci4100 Integrated System-PIVKA Assay-Product Status 20

Table 17: ARCHITECT ci4100 Integrated System-PIVKA Assay-Product Description 20

Table 18: ARCHITECT ci8200 Integrated System-PIVKA Assay-Product Status 20

Table 19: ARCHITECT ci8200 Integrated System-PIVKA Assay-Product Description 20

Table 20: ARCHITECT i4000SR System-PIVKA II Assay-Product Status 21

Table 21: ARCHITECT i4000SR System-PIVKA II Assay-Product Description 21

Table 22: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 22

Table 23: Biomarker Test-Liver Cancer Diagnostic Tests-Product Status 22

Table 24: Biomarker Test-Liver Cancer Diagnostic Tests-Product Description 22

Table 25: AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview 23

Table 26: Multiplexed Detection-Des-Carboxy Prothrombin-Product Status 23

Table 27: Multiplexed Detection-Des-Carboxy Prothrombin-Product Description 23

Table 28: Multiplexed Detection-Matrix metalloproteinase 1-Product Status 24

Table 29: Multiplexed Detection-Matrix metalloproteinase 1-Product Description 24

Table 30: Multiplexed Detection-Procollagen type III N-terminal peptide-Product Status 24

Table 31: Multiplexed Detection-Procollagen type III N-terminal peptide-Product Description 25

Table 32: BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 26

Table 33: Biomarker Assay-Hepatocellular Cancer-Product Status 26

Table 34: Biomarker Assay-Hepatocellular Cancer-Product Description 26

Table 35: Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 27

Table 36: MBDAA Liver Cancer Test-Product Status 27

Table 37: MBDAA Liver Cancer Test-Product Description 27

Table 38: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 28

Table 39: Diagnostic Kit-Liver Cancer Diagnostic Tests-Product Status 28

Table 40: Diagnostic Kit-Liver Cancer Diagnostic Tests-Product Description 28

Table 41: Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 29

Table 42: HCC Molecular Marker Assay-Product Status 29

Table 43: HCC Molecular Marker Assay-Product Description 29

Table 44: Oxidated APO-A1 Assay-Product Status 30

Table 45: Oxidated APO-A1 Assay-Product Description 30

Table 46: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 31

Table 47: Blood-based Liver Cancer Test-Product Status 31

Table 48: Blood-based Liver Cancer Test-Product Description 31

Table 49: DNA Biomarkers-Hepatocellular Carcinoma-Product Status 32

Table 50: DNA Biomarkers-Hepatocellular Carcinoma-Product Description 32

Table 51: Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 33

Table 52: Lumipulse G-PIVKA-II Assay-Product Status 33

Table 53: Lumipulse G-PIVKA-II Assay-Product Description 33

Table 54: German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 34

Table 55: RAGE Based Diagnostic Assay-Liver Cancer Diagnostic Tests-Product Status 34

Table 56: RAGE Based Diagnostic Assay-Liver Cancer Diagnostic Tests-Product Description 34

Table 57: Glycotest Inc Pipeline Products & Ongoing Clinical Trials Overview 35

Table 58: HCC Panel-Product Status 35

Table 59: HCC Panel-Product Description 35

Table 60: ImCare Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview 36

Table 61: HepatoDetect Diagnostic Kit-Product Status 36

Table 62: HepatoDetect Diagnostic Kit-Product Description 36

Table 63: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 37

Table 64: Diagnostic Assay-HCC-Product Status 37

Table 65: Diagnostic Assay-HCC-Product Description 37

Table 66: IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 38

Table 67: Diagnostic Test-Hepatocellular Carcinoma-Product Status 38

Table 68: Diagnostic Test-Hepatocellular Carcinoma-Product Description 38

Table 69: Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39

Table 70: VeraMarker LCS (Liver Cancer Screening) Test-Product Status 39

Table 71: VeraMarker LCS (Liver Cancer Screening) Test-Product Description 39

Table 72: VeraMarker Liver Cancer Screening Test-Hepatitis-Product Status 40

Table 73: VeraMarker Liver Cancer Screening Test-Hepatitis-Product Description 40

Table 74: Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 41

Table 75: Glycan-Based Biomarker Assay-Liver Cancer Diagnostic Tests-Product Status 41

Table 76: Glycan-Based Biomarker Assay-Liver Cancer Diagnostic Tests-Product Description 41

Table 77: Medical University of Vienna Pipeline Products & Ongoing Clinical Trials Overview 42

Table 78: sAXL Biomarker Test-Hepatocellular Carcinoma-Product Status 42

Table 79: sAXL Biomarker Test-Hepatocellular Carcinoma-Product Description 42

Table 80: NanoString Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 43

Table 81: In Vitro Diagnostic Assay-HCC Gene Signature-Product Status 43

Table 82: In Vitro Diagnostic Assay-HCC Gene Signature-Product Description 43

Table 83: Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 44

Table 84: EarlyCDT-Liver Cancer Kit-Product Status 44

Table 85: EarlyCDT-Liver Cancer Kit-Product Description 44

Table 86: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 45

Table 87: Diagnostic Assay-Liver Cancer Diagnostic Tests-Product Status 45

Table 88: Diagnostic Assay-Liver Cancer Diagnostic Tests-Product Description 45

Table 89: PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 46

Table 90: HCCpleX-Product Status 46

Table 91: HCCpleX-Product Description 46

Table 92: ProMIS Neurosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 47

Table 93: Screening Test-Liver Cancer Diagnostic Tests-Product Status 47

Table 94: Screening Test-Liver Cancer Diagnostic Tests-Product Description 47

Table 95: Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 48

Table 96: Biomarker Diagnostic Test-Liver Cancer Diagnostic Tests-Product Status 48

Table 97: Biomarker Diagnostic Test-Liver Cancer Diagnostic Tests-Product Description 48

Table 98: Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 49

Table 99: Biomarker Assay-Liver Cancer Diagnostic Tests-Product Status 49

Table 100: Biomarker Assay-Liver Cancer Diagnostic Tests-Product Description 49

Table 101: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 50

Table 102: Cobas 8000 Analyzer Series With e 801 Module-PIVKA Assay-Product Status 50

Table 103: Cobas 8000 Analyzer Series With e 801 Module-PIVKA Assay-Product Description 50

Table 104: Glypican-3 MAb Companion Diagnostic Test-Product Status 51

Table 105: Glypican-3 MAb Companion Diagnostic Test-Product Description 51

Table 106: University of Louisville Pipeline Products & Ongoing Clinical Trials Overview 52

Table 107: Diagnostic Test-Hepatocellular Carcinoma-Product Status 52

Table 108: Diagnostic Test-Hepatocellular Carcinoma-Product Description 52

Table 109: University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 53

Table 110: Biomarker Test-HCC-Product Status 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Abbott Diagnostics

Abcodia Ltd

AXO Science SAS

BioMark Technologies Inc

Bioprognos SL

China Sky One Medical Inc

Digna Biotech SL

Exact Sciences Corp

Fujirebio Diagnostics Inc

German Cancer Research Center

Glycotest Inc

ImCare Biotech LLC

Imperial College London

IntegraGen SA

Matrix-Bio, Inc.

Medical University of South Carolina

Medical University of Vienna

NanoString Technologies Inc

Oncimmune (USA) LLC

Orion Genomics LLC

PleX Diagnostics Inc

ProMIS Neurosciences Inc

Proplex Technologies Llc

Proteome Sciences Plc

Roche Diagnostics International Ltd

University of Louisville

University of Rochester

Ventana Medical Systems Inc

Viomics Inc.

XEPTAGEN SpA

Ymir Genomics LLC.

Abbott Diagnostics, ARCHITECT c16000 System - PIVKA Assay; Abbott Diagnostics, ARCHITECT c4000 System - PIVKA Assay; Abbott Diagnostics, ARCHITECT c8000 System - PIVKA Assay; Abbott Diagnostics, ARCHITECT ci16200 Integrated System - PIVKA Assay; Abbott Diagnostics, ARCHITECT ci4100 Integrated System - PIVKA Assay; Abbott Diagnostics, ARCHITECT ci8200 Integrated System - PIVKA Assay; Abbott Diagnostics, ARCHITECT i4000SR System - PIVKA II Assay; Abcodia Ltd, Biomarker Test - Liver Cancer; AXO Science SAS, Multiplexed Detection - Des-Carboxy Prothrombin; AXO Science SAS, Multiplexed Detection - Matrix metalloproteinase 1; AXO Science SAS, Multiplexed Detection - Procollagen type III N-terminal peptide; BioMark Technologies Inc, Biomarker Assay - Hepatocellular Cancer; Bioprognos SL, MBDAA Liver Cancer Test; China Sky One Medical Inc, Diagnostic Kit - Liver Cancer; Digna Biotech SL, HCC Molecular Marker Assay; Digna Biotech SL, Oxidated APO-A1 Assay; Exact Sciences Corp, Blood-based Liver Cancer Test; Exact Sciences Corp, DNA Biomarkers - Hepatocellular Carcinoma; Fujirebio Diagnostics Inc, Lumipulse G - PIVKA-II Assay; German Cancer Research Center, RAGE Based Diagnostic Assay - Liver Cancer; Glycotest Inc, HCC Panel; ImCare Biotech LLC, HepatoDetect Diagnostic Kit; Imperial College London, Diagnostic Assay - HCC; IntegraGen SA, Diagnostic Test - Hepatocellular Carcinoma; Matrix-Bio, Inc., VeraMarker LCS (Liver Cancer Screening) Test; Matrix-Bio, Inc., VeraMarker Liver Cancer Screening Test - Hepatitis; Medical University of South Carolina, Glycan-Based Biomarker Assay - Liver Cancer; Medical University of Vienna, sAXL Biomarker Test - Hepatocellular Carcinoma; NanoString Technologies Inc, In Vitro Diagnostic Assay - HCC Gene Signature; Oncimmune (USA) LLC, EarlyCDT - Liver Cancer Kit; Orion Genomics LLC, Diagnostic Assay - Liver Cancer; PleX Diagnostics Inc (Inactive), HCCpleX; ProMIS Neurosciences Inc, Screening Test - Liver Cancer; Proplex Technologies Llc, Biomarker Diagnostic Test - Liver Cancer; Proteome Sciences Plc, Biomarker Assay - Liver Cancer; Roche Diagnostics International Ltd, Cobas 8000 Analyzer Series With e 801 Module - PIVKA Assay; Roche Diagnostics International Ltd, Glypican-3 MAb Companion Diagnostic Test; University of Louisville, Diagnostic Test - Hepatocellular Carcinoma; University of Rochester, Biomarker Test - HCC; Ventana Medical Systems Inc, BLU-554 Companion Diagnostic Assay - Hepatocellular Carcinoma; Viomics Inc., Diagnostic Assay - Liver Cancer; XEPTAGEN SpA, DCP-IgM Kit - Liver Cancer; XEPTAGEN SpA, GPC3-IgM Kit - Liver Cancer; XEPTAGEN SpA, Osteopontin-IgM Kit - Liver Cancer; XEPTAGEN SpA, Survivin-IgM Kit - Liver Cancer; XEPTAGEN SpA, VEGF-IgM Kit - Liver Cancer; Ymir Genomics LLC., Diagnostic Assay - Hepatocellular Carcinoma

select a license
Single User License
USD 4000 INR 285360
Site License
USD 8000 INR 570720
Corporate User License
USD 12000 INR 856080

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com